Medistim ASA

• Medistim initiates the PATENT study, a multicenter trial, to assess the clinical benefits of intraoperative completion control using TTFM and HFUS in patients undergoing bypass surgery for Critical Limb Threatening Ischemia (CLTI). • The study aims to enroll 450 patients across 15 sites in the USA, Europe, and Asia, with recruitment starting by the end of 2024, to evaluate both immediate and one-year clinical outcomes. • The PATENT study seeks to determine the prognostic value of TTFM and HFUS in predicting one-year clinical outcomes, distinguishing patients at high risk of graft failure from those at low risk. • Medistim anticipates that the study's findings will drive the adoption of their MiraQ devices, enhancing competitiveness against traditional methods like Doppler ultrasound and angiography.

Medistim Launches PATENT Study to Improve Outcomes in Critical Limb Ischemia Bypass Surgery